STOCKHOLM – July 10, 2024. Umecrine Cognition today announces that the company has performed a capital raise amounting to SEK 28,3 million according to plan to continue the development of its…
STOCKHOLM – June 28, 2024. Umecrine Cognition today announces that the company has published new nonclinical data in the journal Frontiers in Aging Neuroscience, showing the beneficial effects of…
STOCKHOLM – June 3, 2024. Umecrine Cognition today announces that the company will attend the BIO International Convention in San Diego, USA. The meeting takes place June 3–6th and is expected to…
STOCKHOLM – May 8, 2024. Umecrine Cognition today announces that the first two patients have been randomized into the second part of the company’s ongoing clinical Phase 1b/2 study of…
STOCKHOLM – April 30, 2024. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 2:00 p.m. on Tuesday 28 May 2024 at…
STOCKHOLM – April 16, 2024. Umecrine Cognition today announces that the company has co-authored a scientific review article with leading experts in the research field on the respective roles of the…
STOCKHOLM – March 22, 2024. Umecrine Cognition today announces the successful completion of the first part (Part A) of its ongoing clinical Phase 1b/2 study in Primary Biliary Cholangitis. Part A…
STOCKHOLM – March 18, 2024. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Barcelona, Spain. The meeting takes place March 18–20th and is expected to…
STOCKHOLM – March 15, 2024. Umecrine Cognition today announces that the company has contributed to a review article outlining the scientific support of its lead candidate drug golexanolone and its…
STOCKHOLM – March 6, 2024. Umecrine Cognition today announces that the company will attend the 18th International Conference on Alzheimer’s and Parkinson’s Diseases 2024 in Lisbon, Portugal,…